Filed - Glenmark

NCE Pipeline
Lead Target Indication Stage Status
GRC
10801
CB 1 Obesity Ph I in
Q4
FY07
• Though Rimonabant (Sanofi-Aventis) is approved
in EU, not an ideal candidate due to safety aspects
• Glenmark’s lead target profile will clearly
differentiate us on aspects of safety and drug
metabolism
• Though lead will enter Ph I in end-FY07, we expect
to be third/fourth in class with a clear differential
over existing compounds
GRC
4039
PDE 4
Rheumatoid
Arthritis,
Inflammation
Ph I in
Q1
FY08
• After the withdrawal/setback of COX-2s and the
void that exists in RA therapy, we believe this
could be a potential block-buster opportunity
• The lead is also showing promise in Animal
models in RA and other inflammatory conditions
11